Posted by DaveH (126.96.36.199) on January 07, 2002 at 21:27:52:
Abortive - Triptans
Drug Approval Status:
No peer-reviewed journal article describing frovatriptan's effectiveness in treating migraine has been published. Clinical information is available only in abstract form.
Frovatriptan has a long half-life compared with the other triptans. This means that frovatriptan is present in the body for longer time periods. The benefit of a longer half-life should be a lower rate of headache recurrence. From the limited data available, the rate of migraine recurrence after treatment with frovatriptan appears to be much less than seen with the other triptans.
Two hours after treatment, up to almost half of patients in a clinical study experienced headache relief with different doses of frovatriptan. Headache free rates were not noted.
This medication may be particular useful for those whose migraines tend to recur after treatment.
Likely to be similar to the other triptans.
A preliminary study of VML251 (SB209509) a novel 5HT1B/1D agonist for the treatment of acute migraine.(abstract)
Post a Followup